IMPLANTABLE COLLAMER LENS: STEP AHEAD IN REFRACTIVE SURGERY?

Implantable Collamer Lenses (ICL) represent a significant advancement in ophthalmic refractive surgery, particularly for individuals with high myopia and hyperopia who are ineligible for LASIK or SMILE procedures. First introduced by STAAR Surgical in 1993, ICLs are composed of biocompatible collamer, offering superior visual correction. This article provides a comprehensive review of ICL usage, lens sizing, and postoperative outcomes.

This review utilized various databases, including PubMed, Google Scholar, Scopus, and others, covering publications until October 2024.

ICL implantation is indicated for patients with high myopia (−8 diopters or greater) and hyperopia. Key eligibility criteria include stable refraction, anterior chamber depth, and a central endothelial cell count exceeding 2,200 cells/mm². Postoperative results revealed high patient satisfaction, with 86% achieving uncorrected visual acuity (UDVA) of 20/20 or better.

ICL sizing is crucial, with complications such as pigment dispersion syndrome or cataract formation occurring due to incorrect lens size. Postoperative results demonstrate predictable refractive outcomes and minimal adverse effects when proper sizing and implantation techniques are followed.

ICL offers a safe and effective solution for treating high myopia, providing stable and predictable visual improvements. Long-term studies are needed to address potential complications and optimize lens sizing techniques.